Literature DB >> 22317760

Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.

Katerina Politi1, Thomas J Lynch.   

Abstract

Most lung adenocarcinoma-associated EGF receptor (EGFR) mutations confer sensitivity to specific EGFR tyrosine kinase inhibitors. The finding that exon 19 insertion mutations are also sensitive to this class of drugs suggests that testing for these mutations should be done and that these patients will benefit from treatment with tyrosine kinase inhibitors.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22317760      PMCID： PMC3329215          DOI： 10.1158/1078-0432.CCR-11-3282

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

Review 2.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

Authors:  William Pao; Juliann Chmielecki
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

3.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

4.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

5.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

6.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

Review 7.  Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.

Authors:  Tetsuya Mitsudomi; Yasushi Yatabe
Journal:  FEBS J       Date:  2009-11-18       Impact factor: 5.542

Review 8.  Structure and clinical relevance of the epidermal growth factor receptor in human cancer.

Authors:  Amit Kumar; Edward T Petri; Balazs Halmos; Titus J Boggon
Journal:  J Clin Oncol       Date:  2008-04-01       Impact factor: 44.544

9.  Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.

Authors:  Heidi Greulich; Tzu-Hsiu Chen; Whei Feng; Pasi A Jänne; James V Alvarez; Mauro Zappaterra; Sara E Bulmer; David A Frank; William C Hahn; William R Sellers; Matthew Meyerson
Journal:  PLoS Med       Date:  2005-10-04       Impact factor: 11.069

10.  Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Authors:  William Pao; Vincent A Miller; Katerina A Politi; Gregory J Riely; Romel Somwar; Maureen F Zakowski; Mark G Kris; Harold Varmus
Journal:  PLoS Med       Date:  2005-02-22       Impact factor: 11.069
View more
  10 in total

1.  Biomarker testing in non-small cell lung cancer: to move forward with quality.

Authors:  Rolf Stahel
Journal:  Clin Transl Oncol       Date:  2012-05       Impact factor: 3.405

2.  Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma.

Authors:  Giuseppina Improta; Angela Zupa; Maria Iole Natalicchio; Lorenza Sisinni; Anna Marinaccio; Giovanni Bozza; Giulia Vita; Michele Aieta; Matteo Landriscina
Journal:  Med Oncol       Date:  2018-01-31       Impact factor: 3.064

3.  Altered conformational landscape and dimerization dependency underpins the activation of EGFR by αC-β4 loop insertion mutations.

Authors:  Zheng Ruan; Natarajan Kannan
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-13       Impact factor: 11.205

4.  Indel detection from RNA-seq data: tool evaluation and strategies for accurate detection of actionable mutations.

Authors:  Zhifu Sun; Aditya Bhagwate; Naresh Prodduturi; Ping Yang; Jean-Pierre A Kocher
Journal:  Brief Bioinform       Date:  2017-11-01       Impact factor: 11.622

5.  Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC.

Authors:  Anantbhushan Ranade; Darshana Patil; Amit Bhatt; Rucha Dhasare; Vineet Datta; Rajan Datar; Dadasaheb Akolkar
Journal:  J Pers Med       Date:  2019-07-05

6.  Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non-Small Cell Lung Cancer and Response to EGFR TKIs.

Authors:  Chun-Wei Xu; Lei Lei; Wen-Xian Wang; Li Lin; You-Cai Zhu; Hong Wang; Li-Yun Miao; Li-Ping Wang; Wu Zhuang; Mei-Yu Fang; Tang-Feng Lv; Yong Song
Journal:  Transl Oncol       Date:  2020-05-31       Impact factor: 4.243

7.  Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.

Authors:  Nahomi Tokudome; Yasuhiro Koh; Hiroaki Akamatsu; Daichi Fujimoto; Isamu Okamoto; Kazuhiko Nakagawa; Toyoaki Hida; Fumio Imamura; Satoshi Morita; Nobuyuki Yamamoto
Journal:  BMC Cancer       Date:  2020-02-06       Impact factor: 4.430

8.  Identification of candidate genes for lung cancer somatic mutation test kits.

Authors:  Yong Chen; Jian-Xin Shi; Xu-Feng Pan; Jian Feng; Heng Zhao
Journal:  Genet Mol Biol       Date:  2013-08-30       Impact factor: 1.771

9.  Indel sensitive and comprehensive variant/mutation detection from RNA sequencing data for precision medicine.

Authors:  Naresh Prodduturi; Aditya Bhagwate; Jean-Pierre A Kocher; Zhifu Sun
Journal:  BMC Med Genomics       Date:  2018-09-14       Impact factor: 3.063

Review 10.  Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies.

Authors:  Karam Khaddour; Sushma Jonna; Alexander Deneka; Jyoti D Patel; Mohamed E Abazeed; Erica Golemis; Hossein Borghaei; Yanis Boumber
Journal:  Cancers (Basel)       Date:  2021-06-24       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.